REGENXBIO Set to Host Webcast on Breakthrough Gene Therapy
REGENXBIO Inc. (Nasdaq: RGNX) is excited to announce a forthcoming webcast where they will share interim functional data from the Phase I/II AFFINITY DUCHENNE trial focused on RGX-202. This innovative investigational gene therapy is designed to address Duchenne muscular dystrophy (DMD), a severe muscle-wasting condition. The event promises to provide valuable insights into the ongoing research and progress of this significant treatment.
Featured Speaker and Event Details
Aravindhan Veerapandiyan, M.D., the principal investigator of the AFFINITY DUCHENNE trial, will lead the discussion. Dr. Veerapandiyan is affiliated with Arkansas Children's Hospital and is known for his expertise in this area. He will be presenting the latest findings, which are expected to shed light on the efficacy and potential of RGX-202 in treating this challenging condition.
Event Information
The webcast is scheduled for a morning session where participants can join in to ask questions and gain deeper understanding. As the session progresses, they will explore the data collected and discuss implications for future treatments. Interested individuals can access the webcast through REGENXBIO's official website. An archived version will also be available for those who cannot attend live, ensuring wide reach to stakeholders and the community.
About REGENXBIO Inc.
Founded in 2009, REGENXBIO has quickly established itself as a key player in the gene therapy industry. The company is committed to enhancing patient lives through its pioneering work in adeno-associated virus (AAV) gene therapy. The pipeline includes several groundbreaking one-time treatments for rare and retinal diseases, encompassing not just RGX-202, but also collaborations with Nippon Shinyaku on RGX-121 and RGX-111 for mucopolysaccharidoses, and ABBV-RGX-314 in partnership with AbbVie for retinal diseases.
Transforming Healthcare with Innovation
REGENXBIO's therapies aim to address significant unmet needs in healthcare. Thousands of patients have already benefited from their AAV platform, showcasing the promise these innovations hold. The focus on rare diseases illustrates the company's dedication to areas with critical therapeutic gaps, making their advances all the more impactful.
Future Outlook
Looking ahead, REGENXBIO remains committed to its mission of delivering transformative therapies. The upcoming webcast is part of their ongoing efforts to engage with stakeholders and share updates on their research initiatives. By investing in the development of effective treatments for debilitating conditions like DMD, REGENXBIO is poised to make a lasting impact in the biotechnology field.
Frequently Asked Questions
What is RGX-202?
RGX-202 is an investigational gene therapy aimed at treating Duchenne muscular dystrophy by delivering a working copy of the dystrophin gene to muscle cells.
Who is presenting at the webcast?
Dr. Aravindhan Veerapandiyan, the principal investigator of the AFFINITY DUCHENNE trial, will be the featured presenter.
How can I access the webcast?
The webcast can be accessed through REGENXBIO's official website, with an archived version available shortly after the event.
What is the importance of the AFFINITY DUCHENNE trial?
This trial is critical for understanding the efficacy of RGX-202 as a treatment option for patients with Duchenne muscular dystrophy, providing essential data for future developments.
What does REGENXBIO aim to achieve?
REGENXBIO aims to improve healthcare outcomes through innovative gene therapies targeted at rare diseases and conditions, enhancing the quality of life for affected individuals.
